PROVECTUS BIOPHARMACEUTICALS, INC.

Form SC 13D March 30, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Provectus Biopharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

74373F100

(CUSIP Number)

Courtlandt G. Miller

251 Royal Palm Way, Suite 205

Palm Beach, FL 33480

(561) 543-6802

with copies to:

David W. Bernstein, Esq.

Goodwin Procter LLP

620 Eighth Avenue

New York, NY 10018

(212) 813-8808

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 19, 2017

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box .

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

(Continued on following pages)

1	Name of Reporting Persons		
2	Charles Check	the A	lejohn Appropriate Box if a Member of a Group* D)
3	SEC Use Only		
4	Source of Funds*		
5	PF Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6	6 Citizenship or Place of Organization		
	United States		
Num			Sole Voting Power
Sh	ares		
Bene	ficially		1,956,790
Owned by		8	Shared Voting Power
Е	ach		
Rep	orting	9	0 Sole Dispositive Power
Person			
W	Vith	10	1,956,790 Shared Dispositive Power

	0
11	Aggregate Amount Beneficially Owned by Each Reporting Person
12	1,956,790 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.540% Type of Reporting Person*

* SEE INSTRUCTIONS BEFORE FILLING OUT!

IN

1	Name of Reporting Persons		
2	Jeffrey Check (a)	the A	Morris Appropriate Box if a Member of a Group*
3	SEC Use Only		
4	Source of Funds*		
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6	6 Citizenship or Place of Organization		
	United	State	es
Num			Sole Voting Power
Sh	ares		
Bene	ficially		17,000,000
Owned by		8	Shared Voting Power
Е	ach		
Rep	orting	9	0 Sole Dispositive Power
Pe	rson		
W	Vith	10	17,000,000 Shared Dispositive Power

	0
11	Aggregate Amount Beneficially Owned by Each Reporting Person
	17,000,000
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
13	Teresit of Class Represented by Amount in Row (11)
	4.66%
14	Type of Reporting Person*

* SEE INSTRUCTIONS BEFORE FILLING OUT!

IN

1	Name of Reporting Persons		
2		the A	yle Jr Credit Shelter Trust Appropriate Box if a Member of a Group* o)
3	SEC Use Only		
4	Source of Funds*		
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6	6 Citizenship or Place of Organization		
	United	State	es
Num			Sole Voting Power
Sh	ares		
Bene	ficially		15,000
Owned by		8	Shared Voting Power
Е	ach		
Rep	orting	9	0 Sole Dispositive Power
Person			
W	Vith	10	15,000 Shared Dispositive Power

Aggregate Amount Beneficially Owned by Each Reporting Person

15,000
12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*

13 Percent of Class Represented by Amount in Row (11)

0.04%

14 Type of Reporting Person*

OO

* SEE INSTRUCTIONS BEFORE FILLING OUT!

1	Name of Reporting Persons		
2	John G Check (a)	the A	zonas Appropriate Box if a Member of a Group*
3	SEC Use Only		
4	Source of Funds*		
5	PF Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6	6 Citizenship or Place of Organization		
	United States		
Num			Sole Voting Power
Sh	ares		
Bene	ficially		2,350,000
Owned by		8	Shared Voting Power
Е	ach		
Rep	orting	9	0 Sole Dispositive Power
Person			
W	/ith	10	2,350,000 Shared Dispositive Power

11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	2,350,000 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.64% Type of Reporting Person*

IN

* SEE INSTRUCTIONS BEFORE FILLING OUT!

1	Name of Reporting Persons		
2	James 1 Check	the A	Vatson Appropriate Box if a Member of a Group* b)
3	SEC Use Only		
4	Source of Funds*		
5	PF Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6	6 Citizenship or Place of Organization		
	United	State	es
Nun			Sole Voting Power
Sh	ares		
Bene	ficially		500,000
Owned by		8	Shared Voting Power
Е	ach		
Rep	orting	9	0 Sole Dispositive Power
Pe	rson		
V	Vith	10	1,000,000 Shared Dispositive Power

	Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC Form SC 13D
11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	1,000,000 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*

13 Percent of Class Represented by Amount in Row (11)

0.27%

14 Type of Reporting Person*

IN

* SEE INSTRUCTIONS BEFORE FILLING OUT!

1	Name of Reporting Persons		
2	Times Check (a)	the A	LC Appropriate Box if a Member of a Group* b)
3	SEC Use Only		
4	Source of Funds*		
5	OO Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6	6 Citizenship or Place of Organization		
	United States		
Num			Sole Voting Power
Sh	nares		
Bene	ficially		532,000
Owned by		8	Shared Voting Power
Е	ach		0
Rep	orting	9	0 Sole Dispositive Power
Pe	erson		
V	Vith	10	1,330,000 Shared Dispositive Power

11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	1,330,000 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.36% Type of Reporting Person*

* SEE INSTRUCTIONS BEFORE FILLING OUT!

00

1	Name of Reporting Persons		
2	Steve S Check	the A	Appropriate Box if a Member of a Group*
3	SEC Use Only		
4	Source of Funds*		
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6	6 Citizenship or Place of Organization		
	United	State	es
Num			Sole Voting Power
Sh	ares		
Bene	ficially		780,000
Owned by		8	Shared Voting Power
Е	ach		
Rep	orting	9	0 Sole Dispositive Power
Pe	rson		
W	Vith	10	780,000 Shared Dispositive Power

	Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC Form SC 13L
	0
11	Aggregate Amount Beneficially Owned by Each Reporting Person

780,000 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares* 13 Percent of Class Represented by Amount in Row (11) 0.21% 14 Type of Reporting Person*	11	Aggregate Amount Beneficially Owned by Each Reporting Person
0.21%	12	·
	13	Percent of Class Represented by Amount in Row (11)
	14	

* SEE INSTRUCTIONS BEFORE FILLING OUT!

IN

1	Name of Reporting Persons				
2	Al Schr Check	the A	ck Appropriate Box if a Member of a Group* b)		
3	SEC U	se O	nly		
4	Source	of F	unds*		
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6	6 Citizenship or Place of Organization				
	United States				
Nun			Sole Voting Power		
Sh	nares				
Bene	ficially		45,000		
Owned by		8	Shared Voting Power		
Е	ach				
Rep	orting	9	0 Sole Dispositive Power		
Person					
V	Vith	10	45,000 Shared Dispositive Power		

11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	45,000 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)

0.01%

14 Type of Reporting Person*

IN

* SEE INSTRUCTIONS BEFORE FILLING OUT!

1	Name of Reporting Persons					
2	Marta S Check	the A	renck Appropriate Box if a Member of a Group*			
3	SEC U	se O	nly			
4	Source	of F	unds*			
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)			
6	6 Citizenship or Place of Organization					
	United States					
			Sole Voting Power			
Sh	ares					
Bene	ficially		45,000			
Owned by		8	Shared Voting Power			
Е	ach					
Rep	orting	9	0 Sole Dispositive Power			
Pe	rson					
W	/ith	10	45,000 Shared Dispositive Power			

	Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC Form SC 13D
	0
11	Aggregate Amount Beneficially Owned by Each Reporting Person

45,000

- 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
- 13 Percent of Class Represented by Amount in Row (11)

0.01%

14 Type of Reporting Person*

IN

* SEE INSTRUCTIONS BEFORE FILLING OUT!

1	Name of Reporting Persons				
2	Jean St Check (a)	the A	Appropriate Box if a Member of a Group*		
3	SEC U	se O	nly		
4	Source	of F	unds*		
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6	6 Citizenship or Place of Organization				
	United States				
Nun			Sole Voting Power		
Sh	nares				
Bene	ficially		100,000		
Owned by		8	Shared Voting Power		
Е	ach				
Rep	orting	9	0 Sole Dispositive Power		
Person					
W	Vith	10	100,000 Shared Dispositive Power		

11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	100,000 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.03% Type of Reporting Person*

* SEE INSTRUCTIONS BEFORE FILLING OUT!

IN

1	Name of Reporting Persons				
2	Bill Re Check	the A	rd Appropriate Box if a Member of a Group* b)		
3	SEC U	se O	nly		
4	Source	of F	unds*		
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6	6 Citizenship or Place of Organization				
	United aber of ares		es Sole Voting Power		
Bene	ficially		0		
Owr	ned by	8	Shared Voting Power		
Е	ach		0		
Rep	orting	9	Sole Dispositive Power		
Pe	rson				
W	/ith	10	0 Shared Dispositive Power		

	Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC Form SC 13D
11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	0 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.00% Type of Reporting Person*

* SEE INSTRUCTIONS BEFORE FILLING OUT!

IN

1	Name of Reporting Persons				
2	Scott W Check	the A	er Appropriate Box if a Member of a Group* b)		
3	SEC U	se O	nly		
4	Source	of F	unds*		
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6	6 Citizenship or Place of Organization				
	United States				
Nun			Sole Voting Power		
Sh	nares				
Bene	ficially		60,000		
Owned by		8	Shared Voting Power		
Е	ach				
Rep	orting	9	0 Sole Dispositive Power		
Person					
V	Vith	10	60,000 Shared Dispositive Power		

11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	60,000 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
	0.02%

IN

14

* SEE INSTRUCTIONS BEFORE FILLING OUT!

Type of Reporting Person*

1	Name of Reporting Persons			
2	Hugh C Check	the A	olan Appropriate Box if a Member of a Group* b)	
3	SEC Use Only			
4	Source of Funds*			
5	PF Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)			
6	6 Citizenship or Place of Organization			
	United	State	es.	
Nun			Sole Voting Power	
Sh	nares			
Bene	ficially		250,000	
Owned by		8	Shared Voting Power	
Е	ach			
Rep	orting	9	0 Sole Dispositive Power	
Person				
V	Vith	10	250,000 Shared Dispositive Power	

11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	250,000 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.07% Type of Reporting Person*

IN

* SEE INSTRUCTIONS BEFORE FILLING OUT!

1	Name of Reporting Persons		
2	Marc K Check	the A	y Appropriate Box if a Member of a Group* b)
3	SEC Use Only		
4	Source of Funds*		
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6	6 Citizenship or Place of Organization		
	United	State	es
Num	ber of	7	Sole Voting Power
Sh	ares		
Bene	ficially		34,150
Owned by		8	Shared Voting Power
Е	ach		
Rep	orting	9	0 Sole Dispositive Power
Person			
W	/ith	10	34,150 Shared Dispositive Power

11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	34,150 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.01% Type of Reporting Person*

* SEE INSTRUCTIONS BEFORE FILLING OUT!

IN

1	Name of Reporting Persons		
2		the A	G. Miller Appropriate Box if a Member of a Group* b)
3	SEC U	se O	nly
4	Source of Funds*		
5	PF Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6	6 Citizenship or Place of Organization		
	United	State	es
Nun	nber of	7	
Sh	ares		7,800
Bene	ficially		
Owned by		8	Shared Voting Power
Е	ach		
Rep	orting	9	0 Sole Dispositive Power
Pe	rson		
W	Vith	10	396,370 Shared Dispositive Power

11	Aggregate Amount Beneficially Owned by Each Reporting Person
12	396,370 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.11% Type of Reporting Person*
	IN

1	Name of Reporting Persons		
2	Peter C Check	the A	pper Appropriate Box if a Member of a Group* b)
3	SEC Use Only		
4	Source of Funds*		
5	PF Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6	6 Citizenship or Place of Organization		
	United	State	es
Num			Sole Voting Power
Sh	ares		
Bene	ficially		3,474,998
Owned by		8	Shared Voting Power
Е	ach		
Rep	orting	9	0 Sole Dispositive Power
Person			
W	Vith	10	3,474,998 Shared Dispositive Power

Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC.	- Form	SC 1	13D

11	Aggregate Amount Beneficially Owned by Each Reporting Person
12	3,474,998 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.95% Type of Reporting Person*
	IN

1	Name of Reporting Persons			
2	Robert Taurosa Check the Appropriate Box if a Member of a Group* (a) (b)			
3	SEC U	se O	nly	
4	Source	of F	unds*	
5	PF Check	Box	if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	
6	6 Citizenship or Place of Organization			
	United aber of ares			
Bene	ficially		0	
Own	ned by	8	Shared Voting Power	
E	ach		0	
Rep	orting	9	Sole Dispositive Power	
Person				
W	/ith	10	0 Shared Dispositive Power	

11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	0 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.00% Type of Reporting Person*

* SEE INSTRUCTIONS BEFORE FILLING OUT!

IN

1	Name of Reporting Persons			
2	Calvin Check	the A	len III Appropriate Box if a Member of a Group*	
3	SEC Use Only			
4	Source of Funds*			
5	PF Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)			
6	6 Citizenship or Place of Organization			
	United	State	aç	
Nun			Sole Voting Power	
Sh	nares			
Bene	ficially		0	
Owned by		8	Shared Voting Power	
E	ach			
Rep	orting	9	0 Sole Dispositive Power	
Person				
V	Vith	10	0 Shared Dispositive Power	

	Edgar Filing: PROVECTUS BIOPHARMACEUTICALS, INC Form SC 13D
11	0 Aggregate Amount Beneficially Owned by Each Reporting Person
12	0 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
13	Percent of Class Represented by Amount in Row (11)
14	0.00% Type of Reporting Person*

* SEE INSTRUCTIONS BEFORE FILLING OUT!

IN

Item 1. Security and Issuer

This Schedule 13D (this Statement) relates to common stock, par value \$0.001 per share (Common Stock), of Provectus Biopharmaceuticals, Inc. (the Issuer). The address of the principal executive office of the Issuer is: 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931.

Item 2. Identity and Background

(a) This statement is being filed by Charles Littlejohn, Jeffrey A. Morris, the James F Boyle Jr Credit Shelter Trust, John G. Gazonas, James D. Watson, Times 11, LLC, Steve Smith, Al Schwenck, Marta Schwenck, Jean Stack, Bill Reinhard, Scott Webber, Hugh G. Nolan, Marc Kelley, Courtlandt G. Miller, Peter R. Culpepper, Calvin Wallen III, and Robert Taurosa (together, the Reporting Persons).

The Reporting Persons in the aggregate own beneficially more than 5% of a class of equity securities of the Issuer.

(b) and (c) The addresses and principal occupations of the Reporting Persons are as follows:

	Residence or	Present Principal Occupation;
Name	Business Address	Name and Principal Business
	301 Oakhill Drive	Retired
Charles Littlejohn	Lompoc, CA 93436	
Jeffrey A. Morris	238 Kings Grant Road	President
	Maryville, TN 37801	LDX Optronics Inc.
		Manufacturing lasers
James F Boyle Jr Credit Shelter Trust	2390 Orchard Crest Blvd.	N/A
	Manasquan, NJ 08736	
John G. Gazonas	315-319 Hawthorne Avenue	President
	Point Pleasant, NJ 08742	Pharos Contracting Company Inc.
		General contractor/developer
James D. Watson	400A E. Oceanfront	Owner
	Balboa, CA 92661	Interim HealthCare of Greater NY,

		health care
Times 11, LLC	304 S. Euclid Avenue	N/A
	Westfield, NJ 07090	
Steve Smith	2100 Highway 35	Owner
	Sea Girt, NJ 08750	Wings
		Recreation
Al Schwenck	53 Hillside Terrace	Retired
	Ocean, NJ 07712	
Marta Schwenck	53 Hillside Terrace	Retired
	Ocean, NJ 07712	
Jean Stack	127 Metedeconk	RKS Associates
	Court	Special Needs Services
	Holmdel, NJ 07733	Owner
Bill Reinhard	396 Sycamore Street	
	Manasquan, NJ 08736	Self-Employed
Scott Webber	19 Bradley Road	Builder/Project Manager
	Clark, NJ 07066	Monroe Manor, Inc.
		Home Builders
Hugh G. Nolan	1011 Forrest Road	Self-Employed
	Brielle, NJ 08730	
Marc Kelley	60 Normandie Place	Retired
	Cranford, NJ 07016	
Courtlandt G. Miller	251 Royal Palm Way, Ste 205	Chief Executive Officer
	Palm Beach, FL 33480	Via Verde LLC
		Mirco-wind renewable energy
Peter R. Culpepper	P.O. Box 32489	Self-Employed
	Knoxville, TN 37930	

Robert Taurosa 3401 Shoreline Drive RCT Policies FLP

Allenwood, NJ 08720 Insurance

- (d) Not applicable.
- (e) Not applicable.
- (f) All individual Reporting Persons are U.S. citizens. Times 11 LLC is a Delaware limited liability company that was formed on March 23, 2011.

Item 3. Source and Amount of Funds or Other Consideration Not applicable.

Item 4. Purpose of Transaction

On February 28, 2017, a person representing the Reporting Persons (Investors), informed the Issuer that, if investor commitments for at least \$8 million were obtained, the Investors proposed to purchase for between \$8 million and \$20 million units consisting of common stock and a new Preferred Stock of the Issuer. The communication included a draft Term Sheet relating to the proposed investment. As the Issuer was told that at that time, the Investor commitments were less than the minimum amount necessary to cause agreements regarding the commitments that had been made to be effective. Therefore, the Investors commitments were not at the time effective. One of the conditions to the proposed financing was that all the officers and directors of the Issuer resign and persons designated by the Investors be elected to the Board.

On March 4, 2017, the Issuer issued a press release in which it announced that it had received a proposal from two investor groups, one of which was the Investors. On the same day, the Issuer s lawyers sent a lawyer for representatives of the Investors a brief comparison of the two financing proposals and said that the Issuer s Board had deemed the Investor proposal to be far inferior to the other proposal. On March 8, a representative of the Investors responded, through lawyers, that the Investors had no interest in investing on the terms of the other proposal, and in view of the Board s belief that the Investor proposal was far inferior to the other proposal,

the Investors were withdrawing their proposal. However, the representative of the Investors said that if the other group is not able to provide the described financing, or for any other reason the Issuer s Board decides that it would like to pursue a financing by the Investors on the terms they had proposed, the principal Investors would try to revive that proposal.

Despite the fact that the Investors had withdrawn their proposal, in order to be prepared to provide funds they believe are critical to the Issuer if the Issuer asked them to revive their proposal, by March 19, 2017, all the Investors agreed that they would commit to invest even though there were only \$6 million in commitments. Therefore, their commitments became effective.

On March 20, 2017, the Issuer announced that it had entered into a Definitive Financing Commitment Term Sheet with a group of its shareholders. The press release containing that announcement said that the Issuer had previously received two unsolicited proposals relating to potential equity financings and that its board of directors had rejected the Investors proposal because, among other reasons, the financial terms of [the proposal] were determined to be detrimental to the future of the Company as an ongoing concern. On March 23, 2017, the Issuer filed a Report on Form 8-K with the Securities and Exchange Commission in which it described the terms of an amended and restated Definitive Commitment Term Sheet. What it described was a financing in the form of a secured convertible loan, secured by a first priority security interest in the Issuer s intellectual property.

On March 24, 2017, a representative of the Investors sent a letter to the directors of the Issuer in which he said that the transaction described in the Form 8-K would constitute a waste of corporate assets and that unless the Investors receive assurance by March 27, 2017 that the Issuer will not enter into the transaction described in the Form 8-K, they are going to institute litigation in the Delaware courts to prevent the Issuer from entering into that transaction and to hold the directors personally liable for the costs the Issuer has incurred in connection with that transaction and in connection with a recently terminated rights offering.

On March 27, a lawyer for the Issuer responded by stating that if the Investors made a proposal that did not involve Peter R. Culpepper, the Issuer s Board would consider it. On March 28, 2017, the representative of the Investors responded that they would accept that condition and stated that the Investors would like to begin right away working on the documents regarding the financing transaction they have proposed.

Item 5. Interest in Securities of the Issuer

(a) The aggregate number of Shares to which this Schedule 13D relates is 28,806,558 shares, representing 7.90% of the 364,773,297 shares outstanding as reported by the Issuer in its Form 10-Q filed with the Securities Exchange Commission on November 9, 2016, adjusted to take account of a reset which resulted in the issuance of additional shares. The Reporting Persons own those shares as follows:

	Shares of	% of Class of
Name	Common Stock ⁽¹⁾	Common
Charles Littlejohn	1,956,790	*
Jeffrey A. Morris	17,000,000	4.66%
James F Boyle Jr Credit Shelter Trust	15,000	*
John G. Gazonas	2,350,000	*
James D. Watson	100,000	*
Times 11, LLC	1,330,000	*
Steve Smith	780,000	*

Al Schwenck	45,000	*
Marta Schwenck	45,000	*

Jean Stack	1,000,000	*
Bill Reinhard	0	0.00%
Scott Webber	60,000	*
Hugh G. Nolan	250,000	*
Courtlandt G. Miller	396,370	*
Peter R. Culpepper	3,474,998	*
Robert Taurosa	0	0.00%
Marc Kelley	31,150	*

- (1) Includes shares issuable upon exercise of warrants, which are currently exercisable.
- * Indicates less than 1% ownership.
- (b) Each of the Reporting Persons has the sole power to vote or direct the vote and sole power to dispose or direct the disposition of the shares reported for that person, except that James D. Watson has shared voting power with regard to 500,000 shares.
- (c) John G. Gazonas purchased 28,000 shares of the Issuer s common stock on February 9, 2017 at \$0.021 per share. Jeffrey A. Morris purchase 1,000,000 shares of the Issuer s common stock on March 24, 2017 at \$0.041 per share and 1,000,000 shares of the Issuer s common stock on March 27, 2017 at \$0.047 per share.

Hugh Nolan purchased 55,000 shares of the Issuer s common stock on February 1st, February 8, 2017 at \$0.02.

Item 6. Contracts, Arrangements, Understandings or Relationships with respect to Securities of the Issuer

Not applicable.

Item 7. Material to be Filed as Exhibits

Exhibit 1 Joint Filing Agreement

Exhibit 2 Form of Amended Investment Agreement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 29, 2017 /s/ Courtlandt G. Miller Courtlandt G. Miller